scholarly journals Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria

Diabetes Care ◽  
2011 ◽  
Vol 34 (9) ◽  
pp. 2078-2083 ◽  
Author(s):  
Merel E. Hellemons ◽  
Frederik Persson ◽  
Stephan J.L. Bakker ◽  
Peter Rossing ◽  
Hans-Henrik Parving ◽  
...  
Keyword(s):  
Renal Outcome ◽  
Diabetic Patients ◽  
Receptor Blockade ◽  
Angiotensin Receptor ◽  
Type 2 Diabetic Patients ◽  
Angiotensin Receptor Blockade ◽  
Type 2 Diabetic

scholarly journals Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis

PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e3405 ◽  
Author(s):  
Lubin Xu ◽  
Yang Li ◽  
Jiaxin Lang ◽  
Peng Xia ◽  
Xinyu Zhao ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Function ◽  
Diabetic Patients ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Type 2 Diabetic Patients ◽  
Sglt2 Inhibition ◽  
Type 2 Diabetic

Aim To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes. Methods We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomized controlled trials of SGLT2 inhibitors in adult type 2 diabetic patients reporting estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio (ACR) changes. Data were synthesized using the random-effects model. Results Forty-seven studies with 22,843 participants were included. SGLT2 inhibition was not associated with a significant change in eGFR in general (weighted mean difference (WMD), −0.33 ml/min per 1.73 m2, 95% CI [−0.90 to 0.23]) or in patients with chronic kidney disease (CKD) (WMD −0.78 ml/min per 1.73 m2, 95% CI [−2.52 to 0.97]). SGLT2 inhibition was associated with eGFR reduction in short-term trials (WMD −0.98 ml/min per 1.73 m2, 95% CI [−1.42 to −0.54]), and with eGFR preservation in long-term trials (WMD 2.01 ml/min per 1.73 m2, 95% CI [0.86 to 3.16]). Urine ACR reduction after SGLT2 inhibition was not statistically significant in type 2 diabetic patients in general (WMD −7.24 mg/g, 95% CI [−15.54 to 1.06]), but was significant in patients with CKD (WMD −107.35 mg/g, 95% CI [−192.53 to −22.18]). Conclusions SGLT2 inhibition was not associated with significant changes in eGFR in patients with type 2 diabetes, likely resulting from a mixture of an initial reduction of eGFR and long-term renal function preservation. SGLT2 inhibition was associated with statistically significant albuminuria reduction in type 2 diabetic patients with CKD.

Long-Term Oral L-Arginine Administration Improves Peripheral and Hepatic Insulin Sensitivity in Type 2 Diabetic Patients

Diabetes Care ◽  
2001 ◽  
Vol 24 (5) ◽  
pp. 875-880 ◽  
Author(s):  
P. Piatti ◽  
L. D. Monti ◽  
G. Valsecchi ◽  
F. Magni ◽  
E. Setola ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Hepatic Insulin Sensitivity ◽  
Type 2 Diabetic

scholarly journals Urinary Markers of Nucleic Acid Oxidation and Long-Term Mortality of Newly Diagnosed Type 2 Diabetic Patients

Diabetes Care ◽  
2011 ◽  
Vol 34 (12) ◽  
pp. 2594-2596 ◽  
Author(s):  
K. Broedbaek ◽  
V. Siersma ◽  
T. Henriksen ◽  
A. Weimann ◽  
M. Petersen ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Acid Oxidation ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Urinary Markers ◽  
Type 2 Diabetic ◽  
Long Term Mortality
Sign in / Sign up

Export Citation Format

Share Document